+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Oligonucleotide Therapeutics Market - Global Forecast 2026-2032- Product Image
Oligonucleotide Therapeutics Market - Global Forecast 2026-2032- Product Image
Sale

Oligonucleotide Therapeutics Market - Global Forecast 2026-2032

  • Report

  • 184 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6126521
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Oligonucleotide Therapeutics Market is projected to reach USD 23.73 Billion in 2026. It is expected to continue growing at a CAGR of 6.90%, reaching USD 35.65 Billion by 2032.

Oligonucleotide Therapeutics: Executive Overview

Oligonucleotide therapeutics use short nucleic-acid sequences to modulate gene expression through mechanisms such as antisense activity, RNA interference, exon skipping, and related approaches. Their clinical value is linked to the ability to address targets that may be difficult to influence with conventional small molecules or antibodies. Development priorities increasingly center on delivery, durability, tissue selectivity, safety, manufacturing consistency, and biomarker-supported patient selection.

Delivery, Precision, and Manufacturing Are Reshaping Development

The field is shifting from proof of concept toward broader and more durable therapeutic application. Advances in chemical modification, conjugation, lipid- and ligand-based delivery, and tissue-targeting strategies are intended to improve cellular uptake while reducing off-target effects and dosing burden. At the same time, developers are placing greater emphasis on scalable synthesis, impurity control, analytical characterization, cold-chain requirements, and long-term safety monitoring. Regulatory pathways are also evolving as sponsors generate more evidence on pharmacology, immunogenicity, persistence, and clinical endpoints.

Artificial Intelligence Strengthens Design, Translation, and Operations

Artificial intelligence can support oligonucleotide development by ranking sequence candidates, modeling secondary structure and target interactions, identifying potential off-target activity, and integrating genomic and transcriptomic data. It can also assist with formulation screening, image and biomarker analysis, patient stratification, and manufacturing-process monitoring. These applications remain dependent on high-quality, representative datasets and experimental validation. For leaders, the practical opportunity is to combine machine learning with laboratory evidence, transparent model governance, and controls for data privacy, reproducibility, and bias.

Regional Priorities Differ Across North America, Latin America, Europe, the Middle East, Africa, and Asia-Pacific

North America benefits from deep translational research capabilities, specialized manufacturing, and established regulatory infrastructure. Europe emphasizes coordinated science, advanced therapy governance, health-technology assessment, and manufacturing quality, while the European Union adds cross-border regulatory and reimbursement complexity. Asia-Pacific combines strong research and production capacity with expanding clinical development, particularly across Australia, China, India, Japan, and South Korea. Latin America is important for clinical research access and regional healthcare expansion, although evidence-generation and supply planning must account for diverse regulatory systems. The Middle East is investing in biotechnology, precision medicine, and clinical infrastructure, while Africa presents important unmet-need and research opportunities alongside constraints involving specialized delivery, diagnostics, financing, and distribution.

International Groups Shape Regulation, Trade, Research, and Access

ASEAN cooperation can support regional clinical development and harmonized approaches, but differences in regulatory maturity and healthcare access remain relevant. BRICS members bring substantial scientific, manufacturing, and patient-population capabilities, with varied intellectual-property and reimbursement environments. The European Union supports collaborative research and shared regulatory mechanisms, while national implementation still affects adoption. G7 countries contribute major research, financing, and standards-setting capacity. GCC states are strengthening biotechnology and healthcare infrastructure through coordinated investment, and NATO members may influence biomedical resilience, supply-chain security, and research collaboration. Across these groups, consistent data standards and reliable access to specialized materials are strategic priorities.

Country-Level Conditions Define Clinical and Commercial Execution

The United States and Canada offer advanced research, clinical, and manufacturing ecosystems, with attention to evidence quality, reimbursement, and supply resilience. The United Kingdom, France, Germany, Italy, and Spain combine strong academic and healthcare networks with differing assessment, procurement, and access processes within and alongside European frameworks. China is expanding domestic innovation, clinical capacity, and production while navigating regulatory and data-governance requirements. Japan emphasizes rigorous quality, specialized clinical development, and an aging-population health context; South Korea combines biotechnology capabilities with growing translational capacity. Australia supports research and clinical trials across a geographically dispersed system. India offers extensive scientific and manufacturing talent, while Brazil and Mexico provide important Latin American research and healthcare platforms with varied regulatory and infrastructure conditions. Russia retains scientific capabilities but faces constraints related to international collaboration, supply chains, and access to specialized technologies.

Industry Leaders Should Prioritize Delivery, Evidence, and Resilience

Leaders should select targets with clear human biology, establish delivery strategies early, and build development plans around clinically meaningful biomarkers and durable outcomes. They should use differentiated chemistry and conjugation approaches where these improve tissue exposure, safety, or dosing convenience, while investing in robust analytical methods and process control. Partnerships with academic, clinical, manufacturing, and data-science organizations can close capability gaps, but governance should define intellectual-property ownership, validation standards, and accountability. Regional launch planning should reflect local evidence, reimbursement, diagnostics, and supply requirements. Finally, organizations should maintain dual-source strategies for critical inputs and use artificial intelligence only within a documented, experimentally validated decision framework.

Methodology: Evidence-Led Synthesis of the Oligonucleotide Therapeutics Landscape

This executive summary uses a structured qualitative synthesis of the supplied market scope and established characteristics of oligonucleotide therapeutics. The assessment organizes evidence across therapeutic mechanisms, delivery technologies, clinical development, regulation, manufacturing, artificial intelligence, geography, and stakeholder groups. Regional, group, and country discussion is comparative rather than quantitative and focuses on documented ecosystem conditions, infrastructure, policy context, and execution considerations. No market estimates, shares, forecasts, or company-specific claims are used. Interpretations should be refreshed against current regulatory notices, peer-reviewed research, clinical-trial records, manufacturing guidance, and country-level healthcare policies before investment or operational decisions.

Conclusion: Execution Quality Will Determine the Next Phase

Oligonucleotide therapeutics are progressing through a phase in which delivery performance, durability, safety evidence, manufacturability, and patient selection are as important as sequence design. Artificial intelligence can accelerate discovery and development, but its value depends on validated data and disciplined experimental confirmation. Regional and country conditions will continue to shape trial execution, regulatory review, reimbursement, and supply continuity. Organizations that integrate molecular innovation with translational evidence, resilient manufacturing, responsible data practices, and locally informed access strategies will be better positioned to convert scientific potential into reliable clinical value.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Oligonucleotide Therapeutics Market, by Therapeutic Area
7.1. Introduction
7.2. Cardiovascular
7.3. Infectious Diseases
7.4. Metabolic Disorders
7.5. Neurology
7.5.1. Alzheimer's Disease
7.5.2. Duchenne Muscular Dystrophy
7.5.3. Huntington's Disease
7.6. Oncology
7.6.1. Hematological Malignancies
7.6.2. Solid Tumors
7.7. Ophthalmology
7.8. Rare Diseases
7.8.1. Beta Thalassemia
7.8.2. Familial Hypercholesterolemia
7.8.3. Spinal Muscular Atrophy
8. Oligonucleotide Therapeutics Market, by Technology
8.1. Introduction
8.2. Antisense Oligonucleotide
8.2.1. RNase H Dependent
8.2.2. Steric Blocking
8.3. Aptamer
8.4. CpG Oligodeoxynucleotide
8.5. Mirna
8.5.1. Mirna Inhibitors
8.5.2. Mirna Mimics
8.6. Sirna
8.6.1. Chemically Modified
8.6.2. Unmodified
9. Oligonucleotide Therapeutics Market, by Oligonucleotide Chemistry
9.1. Introduction
9.2. 2'-O-Methyl RNA
9.3. Locked Nucleic Acid
9.4. Morpholino Oligomers
9.5. Peptide Nucleic Acid
9.6. Phosphorothioate Oligonucleotides
10. Oligonucleotide Therapeutics Market, by Delivery Method
10.1. Introduction
10.2. Conjugates
10.3. Direct Injection
10.4. Electroporation
10.5. Lipid Nanoparticles
10.6. Viral Vectors
11. Oligonucleotide Therapeutics Market, by Route Of Administration
11.1. Introduction
11.2. Inhalation
11.3. Intramuscular
11.4. Intravenous
11.5. Oral
11.6. Subcutaneous
12. Oligonucleotide Therapeutics Market, by Product Type
12.1. Introduction
12.2. Diagnostics
12.3. Research Reagents
12.4. Therapeutics
13. Oligonucleotide Therapeutics Market, by End User
13.1. Introduction
13.2. Ambulatory Care Centers
13.3. Hospitals
13.4. Pharmaceutical Companies
13.5. Research Institutes
14. Oligonucleotide Therapeutics Market, by Region
14.1. Introduction
14.2. Asia-Pacific
14.3. North America
14.4. Latin America
14.5. Europe
14.6. Middle East
14.7. Africa
15. Oligonucleotide Therapeutics Market, by Group
15.1. Introduction
15.2. ASEAN
15.3. GCC
15.4. European Union
15.5. BRICS
15.6. G7
15.7. NATO
16. Oligonucleotide Therapeutics Market, by Country
16.1. Introduction
16.2. United States
16.3. Canada
16.4. Mexico
16.5. Brazil
16.6. United Kingdom
16.7. Germany
16.8. France
16.9. Russia
16.10. Italy
16.11. Spain
16.12. China
16.13. India
16.14. Japan
16.15. Australia
16.16. South Korea
17. Competitive Landscape
17.1. Market Share Analysis, 2025
17.2. Market Concentration Analysis, 2025
17.2.1. Concentration Ratio (CR)
17.2.2. Herfindahl Hirschman Index (HHI)
17.3. Recent Developments & Impact Analysis, 2025
17.4. Product Portfolio Analysis, 2025
17.5. Benchmarking Analysis, 2025
18. Company Profiles
18.1. Agilent Technologies, Inc.
18.2. Alnylam Pharmaceuticals, Inc.
18.3. Arrowhead Pharmaceuticals, Inc.
18.4. Biogen Inc.
18.5. Dicerna Pharmaceuticals, Inc.
18.6. Gilead Sciences, Inc.
18.7. Ionis Pharmaceuticals, Inc.
18.8. Merck & Co., Inc.
18.9. Merck KGaA
18.10. Moderna, Inc.
18.11. Nitto Denko Avecia, Inc.
18.12. Novartis AG
18.13. Pfizer Inc.
18.14. Regulus Therapeutics, Inc.
18.15. Sarepta Therapeutics, Inc.
18.16. Wave Life Sciences Ltd.
19. Key Experts
LIST OF FIGURES
FIGURE 1. Global Oligonucleotide Therapeutics Market, Years Considered for the Study
FIGURE 2. Global Oligonucleotide Therapeutics Market, Research Design
FIGURE 3. Global Oligonucleotide Therapeutics Market, Research Framework
FIGURE 4. Global Oligonucleotide Therapeutics Market, Data Triangulation
FIGURE 5. Global Oligonucleotide Therapeutics Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Oligonucleotide Therapeutics Market Size, by Therapeutic Area, 2025 vs 2032 (%)
FIGURE 7. Global Oligonucleotide Therapeutics Market Size, by Therapeutic Area, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Oligonucleotide Therapeutics Market Size, by Technology, 2025 vs 2032 (%)
FIGURE 9. Global Oligonucleotide Therapeutics Market Size, by Technology, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Oligonucleotide Therapeutics Market Size, by Oligonucleotide Chemistry, 2025 vs 2032 (%)
FIGURE 11. Global Oligonucleotide Therapeutics Market Size, by Oligonucleotide Chemistry, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Oligonucleotide Therapeutics Market Size, by Delivery Method, 2025 vs 2032 (%)
FIGURE 13. Global Oligonucleotide Therapeutics Market Size, by Delivery Method, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Oligonucleotide Therapeutics Market Size, by Route Of Administration, 2025 vs 2032 (%)
FIGURE 15. Global Oligonucleotide Therapeutics Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Oligonucleotide Therapeutics Market Size, by Product Type, 2025 vs 2032 (%)
FIGURE 17. Global Oligonucleotide Therapeutics Market Size, by Product Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Oligonucleotide Therapeutics Market Size, by End User, 2025 vs 2032 (%)
FIGURE 19. Global Oligonucleotide Therapeutics Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 20. Global Oligonucleotide Therapeutics Market Size, by Region, 2025 vs 2032 (%)
FIGURE 21. Global Oligonucleotide Therapeutics Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 22. Global Oligonucleotide Therapeutics Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 23. Global Oligonucleotide Therapeutics Market Size, by Country, 2025 vs 2032 (%)
FIGURE 24. Global Oligonucleotide Therapeutics Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 25. Global Oligonucleotide Therapeutics Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Oligonucleotide Therapeutics Market Segmentation & Coverage
TABLE 2. Global Oligonucleotide Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 3. Global Oligonucleotide Therapeutics Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 4. Global Cardiovascular Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Cardiovascular Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Cardiovascular Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Infectious Diseases Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Infectious Diseases Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Infectious Diseases Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Metabolic Disorders Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Metabolic Disorders Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Metabolic Disorders Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Neurology Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Neurology Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Neurology Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Alzheimer's Disease Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Alzheimer's Disease Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Alzheimer's Disease Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Duchenne Muscular Dystrophy Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Duchenne Muscular Dystrophy Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Duchenne Muscular Dystrophy Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Huntington's Disease Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Huntington's Disease Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Huntington's Disease Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Oncology Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global Oncology Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global Oncology Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global Hematological Malignancies Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Hematological Malignancies Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Hematological Malignancies Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global Solid Tumors Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Solid Tumors Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Solid Tumors Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Ophthalmology Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Ophthalmology Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Ophthalmology Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Rare Diseases Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Rare Diseases Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Rare Diseases Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global Beta Thalassemia Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Global Beta Thalassemia Market Size, by Group, 2017-2032 (USD Million)
TABLE 42. Global Beta Thalassemia Market Size, by Country, 2017-2032 (USD Million)
TABLE 43. Global Familial Hypercholesterolemia Market Size, by Region, 2017-2032 (USD Million)
TABLE 44. Global Familial Hypercholesterolemia Market Size, by Group, 2017-2032 (USD Million)
TABLE 45. Global Familial Hypercholesterolemia Market Size, by Country, 2017-2032 (USD Million)
TABLE 46. Global Spinal Muscular Atrophy Market Size, by Region, 2017-2032 (USD Million)
TABLE 47. Global Spinal Muscular Atrophy Market Size, by Group, 2017-2032 (USD Million)
TABLE 48. Global Spinal Muscular Atrophy Market Size, by Country, 2017-2032 (USD Million)
TABLE 49. Global Oligonucleotide Therapeutics Market Size, by Technology, 2017-2032 (USD Million)
TABLE 50. Global Antisense Oligonucleotide Market Size, by Region, 2017-2032 (USD Million)
TABLE 51. Global Antisense Oligonucleotide Market Size, by Group, 2017-2032 (USD Million)
TABLE 52. Global Antisense Oligonucleotide Market Size, by Country, 2017-2032 (USD Million)
TABLE 53. Global RNase H Dependent Market Size, by Region, 2017-2032 (USD Million)
TABLE 54. Global RNase H Dependent Market Size, by Group, 2017-2032 (USD Million)
TABLE 55. Global RNase H Dependent Market Size, by Country, 2017-2032 (USD Million)
TABLE 56. Global Steric Blocking Market Size, by Region, 2017-2032 (USD Million)
TABLE 57. Global Steric Blocking Market Size, by Group, 2017-2032 (USD Million)
TABLE 58. Global Steric Blocking Market Size, by Country, 2017-2032 (USD Million)
TABLE 59. Global Aptamer Market Size, by Region, 2017-2032 (USD Million)
TABLE 60. Global Aptamer Market Size, by Group, 2017-2032 (USD Million)
TABLE 61. Global Aptamer Market Size, by Country, 2017-2032 (USD Million)
TABLE 62. Global CpG Oligodeoxynucleotide Market Size, by Region, 2017-2032 (USD Million)
TABLE 63. Global CpG Oligodeoxynucleotide Market Size, by Group, 2017-2032 (USD Million)
TABLE 64. Global CpG Oligodeoxynucleotide Market Size, by Country, 2017-2032 (USD Million)
TABLE 65. Global Mirna Market Size, by Region, 2017-2032 (USD Million)
TABLE 66. Global Mirna Market Size, by Group, 2017-2032 (USD Million)
TABLE 67. Global Mirna Market Size, by Country, 2017-2032 (USD Million)
TABLE 68. Global Mirna Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 69. Global Mirna Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 70. Global Mirna Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 71. Global Mirna Mimics Market Size, by Region, 2017-2032 (USD Million)
TABLE 72. Global Mirna Mimics Market Size, by Group, 2017-2032 (USD Million)
TABLE 73. Global Mirna Mimics Market Size, by Country, 2017-2032 (USD Million)
TABLE 74. Global Sirna Market Size, by Region, 2017-2032 (USD Million)
TABLE 75. Global Sirna Market Size, by Group, 2017-2032 (USD Million)
TABLE 76. Global Sirna Market Size, by Country, 2017-2032 (USD Million)
TABLE 77. Global Chemically Modified Market Size, by Region, 2017-2032 (USD Million)
TABLE 78. Global Chemically Modified Market Size, by Group, 2017-2032 (USD Million)
TABLE 79. Global Chemically Modified Market Size, by Country, 2017-2032 (USD Million)
TABLE 80. Global Unmodified Market Size, by Region, 2017-2032 (USD Million)
TABLE 81. Global Unmodified Market Size, by Group, 2017-2032 (USD Million)
TABLE 82. Global Unmodified Market Size, by Country, 2017-2032 (USD Million)
TABLE 83. Global Oligonucleotide Therapeutics Market Size, by Oligonucleotide Chemistry, 2017-2032 (USD Million)
TABLE 84. Global 2'-O-Methyl RNA Market Size, by Region, 2017-2032 (USD Million)
TABLE 85. Global 2'-O-Methyl RNA Market Size, by Group, 2017-2032 (USD Million)
TABLE 86. Global 2'-O-Methyl RNA Market Size, by Country, 2017-2032 (USD Million)
TABLE 87. Global Locked Nucleic Acid Market Size, by Region, 2017-2032 (USD Million)
TABLE 88. Global Locked Nucleic Acid Market Size, by Group, 2017-2032 (USD Million)
TABLE 89. Global Locked Nucleic Acid Market Size, by Country, 2017-2032 (USD Million)
TABLE 90. Global Morpholino Oligomers Market Size, by Region, 2017-2032 (USD Million)
TABLE 91. Global Morpholino Oligomers Market Size, by Group, 2017-2032 (USD Million)
TABLE 92. Global Morpholino Oligomers Market Size, by Country, 2017-2032 (USD Million)
TABLE 93. Global Peptide Nucleic Acid Market Size, by Region, 2017-2032 (USD Million)
TABLE 94. Global Peptide Nucleic Acid Market Size, by Group, 2017-2032 (USD Million)
TABLE 95. Global Peptide Nucleic Acid Market Size, by Country, 2017-2032 (USD Million)
TABLE 96. Global Phosphorothioate Oligonucleotides Market Size, by Region, 2017-2032 (USD Million)
TABLE 97. Global Phosphorothioate Oligonucleotides Market Size, by Group, 2017-2032 (USD Million)
TABLE 98. Global Phosphorothioate Oligonucleotides Market Size, by Country, 2017-2032 (USD Million)
TABLE 99. Global Oligonucleotide Therapeutics Market Size, by Delivery Method, 2017-2032 (USD Million)
TABLE 100. Global Conjugates Market Size, by Region, 2017-2032 (USD Million)
TABLE 101. Global Conjugates Market Size, by Group, 2017-2032 (USD Million)
TABLE 102. Global Conjugates Market Size, by Country, 2017-2032 (USD Million)
TABLE 103. Global Direct Injection Market Size, by Region, 2017-2032 (USD Million)
TABLE 104. Global Direct Injection Market Size, by Group, 2017-2032 (USD Million)
TABLE 105. Global Direct Injection Market Size, by Country, 2017-2032 (USD Million)
TABLE 106. Global Electroporation Market Size, by Region, 2017-2032 (USD Million)
TABLE 107. Global Electroporation Market Size, by Group, 2017-2032 (USD Million)
TABLE 108. Global Electroporation Market Size, by Country, 2017-2032 (USD Million)
TABLE 109. Global Lipid Nanoparticles Market Size, by Region, 2017-2032 (USD Million)
TABLE 110. Global Lipid Nanoparticles Market Size, by Group, 2017-2032 (USD Million)
TABLE 111. Global Lipid Nanoparticles Market Size, by Country, 2017-2032 (USD Million)
TABLE 112. Global Viral Vectors Market Size, by Region, 2017-2032 (USD Million)
TABLE 113. Global Viral Vectors Market Size, by Group, 2017-2032 (USD Million)
TABLE 114. Global Viral Vectors Market Size, by Country, 2017-2032 (USD Million)
TABLE 115. Global Oligonucleotide Therapeutics Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 116. Global Inhalation Market Size, by Region, 2017-2032 (USD Million)
TABLE 117. Global Inhalation Market Size, by Group, 2017-2032 (USD Million)
TABLE 118. Global Inhalation Market Size, by Country, 2017-2032 (USD Million)
TABLE 119. Global Intramuscular Market Size, by Region, 2017-2032 (USD Million)
TABLE 120. Global Intramuscular Market Size, by Group, 2017-2032 (USD Million)
TABLE 121. Global Intramuscular Market Size, by Country, 2017-2032 (USD Million)
TABLE 122. Global Intravenous Market Size, by Region, 2017-2032 (USD Million)
TABLE 123. Global Intravenous Market Size, by Group, 2017-2032 (USD Million)
TABLE 124. Global Intravenous Market Size, by Country, 2017-2032 (USD Million)
TABLE 125. Global Oral Market Size, by Region, 2017-2032 (USD Million)
TABLE 126. Global Oral Market Size, by Group, 2017-2032 (USD Million)
TABLE 127. Global Oral Market Size, by Country, 2017-2032 (USD Million)
TABLE 128. Global Subcutaneous Market Size, by Region, 2017-2032 (USD Million)
TABLE 129. Global Subcutaneous Market Size, by Group, 2017-2032 (USD Million)
TABLE 130. Global Subcutaneous Market Size, by Country, 2017-2032 (USD Million)
TABLE 131. Global Oligonucleotide Therapeutics Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 132. Global Diagnostics Market Size, by Region, 2017-2032 (USD Million)
TABLE 133. Global Diagnostics Market Size, by Group, 2017-2032 (USD Million)
TABLE 134. Global Diagnostics Market Size, by Country, 2017-2032 (USD Million)
TABLE 135. Global Research Reagents Market Size, by Region, 2017-2032 (USD Million)
TABLE 136. Global Research Reagents Market Size, by Group, 2017-2032 (USD Million)
TABLE 137. Global Research Reagents Market Size, by Country, 2017-2032 (USD Million)
TABLE 138. Global Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 139. Global Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 140. Global Therapeutics Market Size, by Country, 2017-2032 (USD Million)
TABLE 141. Global Oligonucleotide Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 142. Global Ambulatory Care Centers Market Size, by Region, 2017-2032 (USD Million)
TABLE 143. Global Ambulatory Care Centers Market Size, by Group, 2017-2032 (USD Million)
TABLE 144. Global Ambulatory Care Centers Market Size, by Country, 2017-2032 (USD Million)
TABLE 145. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 146. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 147. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 148. Global Pharmaceutical Companies Market Size, by Region, 2017-2032 (USD Million)
TABLE 149. Global Pharmaceutical Companies Market Size, by Group, 2017-2032 (USD Million)
TABLE 150. Global Pharmaceutical Companies Market Size, by Country, 2017-2032 (USD Million)
TABLE 151. Global Research Institutes Market Size, by Region, 2017-2032 (USD Million)
TABLE 152. Global Research Institutes Market Size, by Group, 2017-2032 (USD Million)
TABLE 153. Global Research Institutes Market Size, by Country, 2017-2032 (USD Million)
TABLE 154. Global Oligonucleotide Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 155. Asia-Pacific Oligonucleotide Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 156. Asia-Pacific Oligonucleotide Therapeutics Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 157. Asia-Pacific Oligonucleotide Therapeutics Market Size, by Neurology, 2017-2032 (USD Million)
TABLE 158. Asia-Pacific Oligonucleotide Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 159. Asia-Pacific Oligonucleotide Therapeutics Market Size, by Rare Diseases, 2017-2032 (USD Million)
TABLE 160. Asia-Pacific Oligonucleotide Therapeutics Market Size, by Technology, 2017-2032 (USD Million)
TABLE 161. Asia-Pacific Oligonucleotide Therapeutics Market Size, by Antisense Oligonucleotide, 2017-2032 (USD Million)
TABLE 162. Asia-Pacific Oligonucleotide Therapeutics Market Size, by Mirna, 2017-2032 (USD Million)
TABLE 163. Asia-Pacific Oligonucleotide Therapeutics Market Size, by Sirna, 2017-2032 (USD Million)
TABLE 164. Asia-Pacific Oligonucleotide Therapeutics Market Size, by Oligonucleotide Chemistry, 2017-2032 (USD Million)
TABLE 165. Asia-Pacific Oligonucleotide Therapeutics Market Size, by Delivery Method, 2017-2032 (USD Million)
TABLE 166. Asia-Pacific Oligonucleotide Therapeutics Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 167. Asia-Pacific Oligonucleotide Therapeutics Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 168. Asia-Pacific Oligonucleotide Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 169. North America Oligonucleotide Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 170. North America Oligonucleotide Therapeutics Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 171. North America Oligonucleotide Therapeutics Market Size, by Neurology, 2017-2032 (USD Million)
TABLE 172. North America Oligonucleotide Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 173. North America Oligonucleotide Therapeutics Market Size, by Rare Diseases, 2017-2032 (USD Million)
TABLE 174. North America Oligonucleotide Therapeutics Market Size, by Technology, 2017-2032 (USD Million)
TABLE 175. North America Oligonucleotide Therapeutics Market Size, by Antisense Oligonucleotide, 2017-2032 (USD Million)
TABLE 176. North America Oligonucleotide Therapeutics Market Size, by Mirna, 2017-2032 (USD Million)
TABLE 177. North America Oligonucleotide Therapeutics Market Size, by Sirna, 2017-2032 (USD Million)
TABLE 178. North America Oligonucleotide Therapeutics Market Size, by Oligonucleotide Chemistry, 2017-2032 (USD Million)
TABLE 179. North America Oligonucleotide Therapeutics Market Size, by Delivery Method, 2017-2032 (USD Million)
TABLE 180. North America Oligonucleotide Therapeutics Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 181. North America Oligonucleotide Therapeutics Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 182. North America Oligonucleotide Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 183. Latin America Oligonucleotide Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 184. Latin America Oligonucleotide Therapeutics Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 185. Latin America Oligonucleotide Therapeutics Market Size, by Neurology, 2017-2032 (USD Million)
TABLE 186. Latin America Oligonucleotide Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 187. Latin America Oligonucleotide Therapeutics Market Size, by Rare Diseases, 2017-2032 (USD Million)
TABLE 188. Latin America Oligonucleotide Therapeutics Market Size, by Technology, 2017-2032 (USD Million)
TABLE 189. Latin America Oligonucleotide Therapeutics Market Size, by Antisense Oligonucleotide, 2017-2032 (USD Million)
TABLE 190. Latin America Oligonucleotide Therapeutics Market Size, by Mirna, 2017-2032 (USD Million)
TABLE 191. Latin America Oligonucleotide Therapeutics Market Size, by Sirna, 2017-2032 (USD Million)
TABLE 192. Latin America Oligonucleotide Therapeutics Market Size, by Oligonucleotide Chemistry, 2017-2032 (USD Million)
TABLE 193. Latin America Oligonucleotide Therapeutics Market Size, by Delivery Method, 2017-2032 (USD Million)
TABLE 194. Latin America Oligonucleotide Therapeutics Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 195. Latin America Oligonucleotide Therapeutics Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 196. Latin America Oligonucleotide Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 197. Europe Oligonucleotide Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 198. Europe Oligonucleotide Therapeutics Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 199. Europe Oligonucleotide Therapeutics Market Size, by Neurology, 2017-2032 (USD Million)
TABLE 200. Europe Oligonucleotide Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 201. Europe Oligonucleotide Therapeutics Market Size, by Rare Diseases, 2017-2032 (USD Million)
TABLE 202. Europe Oligonucleotide Therapeutics Market Size, by Technology, 2017-2032 (USD Million)
TABLE 203. Europe Oligonucleotide Therapeutics Market Size, by Antisense Oligonucleotide, 2017-2032 (USD Million)
TABLE 204. Europe Oligonucleotide Therapeutics Market Size, by Mirna, 2017-2032 (USD Million)
TABLE 205. Europe Oligonucleotide Therapeutics Market Size, by Sirna, 2017-2032 (USD Million)
TABLE 206. Europe Oligonucleotide Therapeutics Market Size, by Oligonucleotide Chemistry, 2017-2032 (USD Million)
TABLE 207. Europe Oligonucleotide Therapeutics Market Size, by Delivery Method, 2017-2032 (USD Million)
TABLE 208. Europe Oligonucleotide Therapeutics Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 209. Europe Oligonucleotide Therapeutics Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 210. Europe Oligonucleotide Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 211. Middle East Oligonucleotide Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 212. Middle East Oligonucleotide Therapeutics Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 213. Middle East Oligonucleotide Therapeutics Market Size, by Neurology, 2017-2032 (USD Million)
TABLE 214. Middle East Oligonucleotide Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 215. Middle East Oligonucleotide Therapeutics Market Size, by Rare Diseases, 2017-2032 (USD Million)
TABLE 216. Middle East Oligonucleotide Therapeutics Market Size, by Technology, 2017-2032 (USD Million)
TABLE 217. Middle East Oligonucleotide Therapeutics Market Size, by Antisense Oligonucleotide, 2017-2032 (USD Million)
TABLE 218. Middle East Oligonucleotide Therapeutics Market Size, by Mirna, 2017-2032 (USD Million)
TABLE 219. Middle East Oligonucleotide Therapeutics Market Size, by Sirna, 2017-2032 (USD Million)
TABLE 220. Middle East Oligonucleotide Therapeutics Market Size, by Oligonucleotide Chemistry, 2017-2032 (USD Million)
TABLE 221. Middle East Oligonucleotide Therapeutics Market Size, by Delivery Method, 2017-2032 (USD Million)
TABLE 222. Middle East Oligonucleotide Therapeutics Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 223. Middle East Oligonucleotide Therapeutics Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 224. Middle East Oligonucleotide Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 225. Africa Oligonucleotide Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 226. Africa Oligonucleotide Therapeutics Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 227. Africa Oligonucleotide Therapeutics Market Size, by Neurology, 2017-2032 (USD Million)
TABLE 228. Africa Oligonucleotide Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 229. Africa Oligonucleotide Therapeutics Market Size, by Rare Diseases, 2017-2032 (USD Million)
TABLE 230. Africa Oligonucleotide Therapeutics Market Size, by Technology, 2017-2032 (USD Million)
TABLE 231. Africa Oligonucleotide Therapeutics Market Size, by Antisense Oligonucleotide, 2017-2032 (USD Million)
TABLE 232. Africa Oligonucleotide Therapeutics Market Size, by Mirna, 2017-2032 (USD Million)
TABLE 233. Africa Oligonucleotide Therapeutics Market Size, by Sirna, 2017-2032 (USD Million)
TABLE 234. Africa Oligonucleotide Therapeutics Market Size, by Oligonucleotide Chemistry, 2017-2032 (USD Million)
TABLE 235. Africa Oligonucleotide Therapeutics Market Size, by Delivery Method, 2017-2032 (USD Million)
TABLE 236. Africa Oligonucleotide Therapeutics Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 237. Africa Oligonucleotide Therapeutics Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 238. Africa Oligonucleotide Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 239. Global Oligonucleotide Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 240. ASEAN Oligonucleotide Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 241. ASEAN Oligonucleotide Therapeutics Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 242. ASEAN Oligonucleotide Therapeutics Market Size, by Neurology, 2017-2032 (USD Million)
TABLE 243. ASEAN Oligonucleotide Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 244. ASEAN Oligonucleotide Therapeutics Market Size, by Rare Diseases, 2017-2032 (USD Million)
TABLE 245. ASEAN Oligonucleotide Therapeutics Market Size, by Technology, 2017-2032 (USD Million)
TABLE 246. ASEAN Oligonucleotide Therapeutics Market Size, by Antisense Oligonucleotide, 2017-2032 (USD Million)
TABLE 247. ASEAN Oligonucleotide Therapeutics Market Size, by Mirna, 2017-2032 (USD Million)
TABLE 248. ASEAN Oligonucleotide Therapeutics Market Size, by Sirna, 2017-2032 (USD Million)
TABLE 249. ASEAN Oligonucleotide Therapeutics Market Size, by Oligonucleotide Chemistry, 2017-2032 (USD Million)
TABLE 250. ASEAN Oligonucleotide Therapeutics Market Size, by Delivery Method, 2017-2032 (USD Million)
TABLE 251. ASEAN Oligonucleotide Therapeutics Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 252. ASEAN Oligonucleotide Therapeutics Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 253. ASEAN Oligonucleotide Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 254. GCC Oligonucleotide Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 255. GCC Oligonucleotide Therapeutics Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 256. GCC Oligonucleotide Therapeutics Market Size, by Neurology, 2017-2032 (USD Million)
TABLE 257. GCC Oligonucleotide Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 258. GCC Oligonucleotide Therapeutics Market Size, by Rare Diseases, 2017-2032 (USD Million)
TABLE 259. GCC Oligonucleotide Therapeutics Market Size, by Technology, 2017-2032 (USD Million)
TABLE 260. GCC Oligonucleotide Therapeutics Market Size, by Antisense Oligonucleotide, 2017-2032 (USD Million)
TABLE 261. GCC Oligonucleotide Therapeutics Market Size, by Mirna, 2017-2032 (USD Million)
TABLE 262. GCC Oligonucleotide Therapeutics Market Size, by Sirna, 2017-2032 (USD Million)
TABLE 263. GCC Oligonucleotide Therapeutics Market Size, by Oligonucleotide Chemistry, 2017-2032 (USD Million)
TABLE 264. GCC Oligonucleotide Therapeutics Market Size, by Delivery Method, 2017-2032 (USD Million)
TABLE 265. GCC Oligonucleotide Therapeutics Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 266. GCC Oligonucleotide Therapeutics Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 267. GCC Oligonucleotide Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 268. European Union Oligonucleotide Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 269. European Union Oligonucleotide Therapeutics Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 270. European Union Oligonucleotide Therapeutics Market Size, by Neurology, 2017-2032 (USD Million)
TABLE 271. European Union Oligonucleotide Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 272. European Union Oligonucleotide Therapeutics Market Size, by Rare Diseases, 2017-2032 (USD Million)
TABLE 273. European Union Oligonucleotide Therapeutics Market Size, by Technology, 2017-2032 (USD Million)
TABLE 274. European Union Oligonucleotide Therapeutics Market Size, by Antisense Oligonucleotide, 2017-2032 (USD Million)
TABLE 275. European Union Oligonucleotide Therapeutics Market Size, by Mirna, 2017-2032 (USD Million)
TABLE 276. European Union Oligonucleotide Therapeutics Market Size, by Sirna, 2017-2032 (USD Million)
TABLE 277. European Union Oligonucleotide Therapeutics Market Size, by Oligonucleotide Chemistry, 2017-2032 (USD Million)
TABLE 278. European Union Oligonucleotide Therapeutics Market Size, by Delivery Method, 2017-2032 (USD Million)
TABLE 279. European Union Oligonucleotide Therapeutics Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 280. European Union Oligonucleotide Therapeutics Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 281. European Union Oligonucleotide Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 282. BRICS Oligonucleotide Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 283. BRICS Oligonucleotide Therapeutics Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 284. BRICS Oligonucleotide Therapeutics Market Size, by Neurology, 2017-2032 (USD Million)
TABLE 285. BRICS Oligonucleotide Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 286. BRICS Oligonucleotide Therapeutics Market Size, by Rare Diseases, 2017-2032 (USD Million)
TABLE 287. BRICS Oligonucleotide Therapeutics Market Size, by Technology, 2017-2032 (USD Million)
TABLE 288. BRICS Oligonucleotide Therapeutics Market Size, by Antisense Oligonucleotide, 2017-2032 (USD Million)
TABLE 289. BRICS Oligonucleotide Therapeutics Market Size, by Mirna, 2017-2032 (USD Million)
TABLE 290. BRICS Oligonucleotide Therapeutics Market Size, by Sirna, 2017-2032 (USD Million)
TABLE 291. BRICS Oligonucleotide Therapeutics Market Size, by Oligonucleotide Chemistry, 2017-2032 (USD Million)
TABLE 292. BRICS Oligonucleotide Therapeutics Market Size, by Delivery Method, 2017-2032 (USD Million)
TABLE 293. BRICS Oligonucleotide Therapeutics Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 294. BRICS Oligonucleotide Therapeutics Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 295. BRICS Oligonucleotide Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 296. G7 Oligonucleotide Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 297. G7 Oligonucleotide Therapeutics Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 298. G7 Oligonucleotide Therapeutics Market Size, by Neurology, 2017-2032 (USD Million)
TABLE 299. G7 Oligonucleotide Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 300. G7 Oligonucleotide Therapeutics Market Size, by Rare Diseases, 2017-2032 (USD Million)
TABLE 301. G7 Oligonucleotide Therapeutics Market Size, by Technology, 2017-2032 (USD Million)
TABLE 302. G7 Oligonucleotide Therapeutics Market Size, by Antisense Oligonucleotide, 2017-2032 (USD Million)
TABLE 303. G7 Oligonucleotide Therapeutics Market Size, by Mirna, 2017-2032 (USD Million)
TABLE 304. G7 Oligonucleotide Therapeutics Market Size, by Sirna, 2017-2032 (USD Million)
TABLE 305. G7 Oligonucleotide Therapeutics Market Size, by Oligonucleotide Chemistry, 2017-2032 (USD Million)
TABLE 306. G7 Oligonucleotide Therapeutics Market Size, by Delivery Method, 2017-2032 (USD Million)
TABLE 307. G7 Oligonucleotide Therapeutics Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 308. G7 Oligonucleotide Therapeutics Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 309. G7 Oligonucleotide Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 310. NATO Oligonucleotide Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 311. NATO Oligonucleotide Therapeutics Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 312. NATO Oligonucleotide Therapeutics Market Size, by Neurology, 2017-2032 (USD Million)
TABLE 313. NATO Oligonucleotide Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 314. NATO Oligonucleotide Therapeutics Market Size, by Rare Diseases, 2017-2032 (USD Million)
TABLE 315. NATO Oligonucleotide Therapeutics Market Size, by Technology, 2017-2032 (USD Million)
TABLE 316. NATO Oligonucleotide Therapeutics Market Size, by Antisense Oligonucleotide, 2017-2032 (USD Million)
TABLE 317. NATO Oligonucleotide Therapeutics Market Size, by Mirna, 2017-2032 (USD Million)
TABLE 318. NATO Oligonucleotide Therapeutics Market Size, by Sirna, 2017-2032 (USD Million)
TABLE 319. NATO Oligonucleotide Therapeutics Market Size, by Oligonucleotide Chemistry, 2017-2032 (USD Million)
TABLE 320. NATO Oligonucleotide Therapeutics Market Size, by Delivery Method, 2017-2032 (USD Million)
TABLE 321. NATO Oligonucleotide Therapeutics Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 322. NATO Oligonucleotide Therapeutics Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 323. NATO Oligonucleotide Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 324. Global Oligonucleotide Therapeutics Market Size, by Country, 2017-2032 (USD Million)
TABLE 325. United States Oligonucleotide Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 326. United States Oligonucleotide Therapeutics Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 327. United States Oligonucleotide Therapeutics Market Size, by Neurology, 2017-2032 (USD Million)
TABLE 328. United States Oligonucleotide Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 329. United States Oligonucleotide Therapeutics Market Size, by Rare Diseases, 2017-2032 (USD Million)
TABLE 330. United States Oligonucleotide Therapeutics Market Size, by Technology, 2017-2032 (USD Million)
TABLE 331. United States Oligonucleotide Therapeutics Market Size, by Antisense Oligonucleotide, 2017-2032 (USD Million)
TABLE 332. United States Oligonucleotide Therapeutics Market Size, by Mirna, 2017-2032 (USD Million)
TABLE 333. United States Oligonucleotide Therapeutics Market Size, by Sirna, 2017-2032 (USD Million)
TABLE 334. United States Oligonucleotide Therapeutics Market Size, by Oligonucleotide Chemistry, 2017-2032 (USD Million)
TABLE 335. United States Oligonucleotide Therapeutics Market Size, by Delivery Method, 2017-2032 (USD Million)
TABLE 336. United States Oligonucleotide Therapeutics Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 337. United States Oligonucleotide Therapeutics Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 338. United States Oligonucleotide Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 339. Canada Oligonucleotide Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 340. Canada Oligonucleotide Therapeutics Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 341. Canada Oligonucleotide Therapeutics Market Size, by Neurology, 2017-2032 (USD Million)
TABLE 342. Canada Oligonucleotide Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 343. Canada Oligonucleotide Therapeutics Market Size, by Rare Diseases, 2017-2032 (USD Million)
TABLE 344. Canada Oligonucleotide Therapeutics Market Size, by Technology, 2017-2032 (USD Million)
TABLE 345. Canada Oligonucleotide Therapeutics Market Size, by Antisense Oligonucleotide, 2017-2032 (USD Million)
TABLE 346. Canada Oligonucleotide Therapeutics Market Size, by Mirna, 2017-2032 (USD Million)
TABLE 347. Canada Oligonu

Companies Mentioned

  • Agilent Technologies, Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • Biogen Inc.
  • Dicerna Pharmaceuticals, Inc.
  • Gilead Sciences, Inc.
  • Ionis Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Merck KGaA
  • Moderna, Inc.
  • Nitto Denko Avecia, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regulus Therapeutics, Inc.
  • Sarepta Therapeutics, Inc.
  • Wave Life Sciences Ltd.

Related Topics

Related Reports

Oligonucleotide Synthesis Market - Global Forecast 2026-2032 - Product Image

Oligonucleotide Synthesis Market - Global Forecast 2026-2032

  • Report
  • 197 Pages
  • Global
From
Oligonucleotide Therapeutics - Global Strategic Business Report - Product Image

Oligonucleotide Therapeutics - Global Strategic Business Report

  • Report
  • 281 Pages
  • Global
From
High-throughput Oligonucleotide Synthesizers Market - Global Forecast 2026-2032 - Product Image

High-throughput Oligonucleotide Synthesizers Market - Global Forecast 2026-2032

  • Report
  • 199 Pages
  • Global
From
Oligonucleotide Therapeutics Market Size, Share & Trends Analysis Report by Oligonucleotide Class, Therapeutic Area, Route of Administration, Region, and Segment Forecasts, 2026-2033 - Product Image

Oligonucleotide Therapeutics Market Size, Share & Trends Analysis Report by Oligonucleotide Class, Therapeutic Area, Route of Administration, Region, and Segment Forecasts, 2026-2033

  • Report
  • 150 Pages
  • Global
From
Oligonucleotide Synthesis - Global Strategic Business Report - Product Image

Oligonucleotide Synthesis - Global Strategic Business Report

  • Report
  • 383 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.